JP2016063839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016063839A5 JP2016063839A5 JP2016017198A JP2016017198A JP2016063839A5 JP 2016063839 A5 JP2016063839 A5 JP 2016063839A5 JP 2016017198 A JP2016017198 A JP 2016017198A JP 2016017198 A JP2016017198 A JP 2016017198A JP 2016063839 A5 JP2016063839 A5 JP 2016063839A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinase
- pair
- sequence
- recognition sites
- respect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25607809P | 2009-10-29 | 2009-10-29 | |
| US61/256,078 | 2009-10-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537099A Division JP5908405B2 (ja) | 2009-10-29 | 2010-10-29 | 多機能性対立遺伝子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148272A Division JP6333316B2 (ja) | 2009-10-29 | 2016-07-28 | 多機能性対立遺伝子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016063839A JP2016063839A (ja) | 2016-04-28 |
| JP2016063839A5 true JP2016063839A5 (cg-RX-API-DMAC10.html) | 2016-09-15 |
| JP6085696B2 JP6085696B2 (ja) | 2017-02-22 |
Family
ID=43244777
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537099A Active JP5908405B2 (ja) | 2009-10-29 | 2010-10-29 | 多機能性対立遺伝子 |
| JP2016017198A Active JP6085696B2 (ja) | 2009-10-29 | 2016-02-01 | 多機能性対立遺伝子 |
| JP2016148272A Active JP6333316B2 (ja) | 2009-10-29 | 2016-07-28 | 多機能性対立遺伝子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537099A Active JP5908405B2 (ja) | 2009-10-29 | 2010-10-29 | 多機能性対立遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016148272A Active JP6333316B2 (ja) | 2009-10-29 | 2016-07-28 | 多機能性対立遺伝子 |
Country Status (13)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102666854B (zh) | 2009-10-29 | 2016-08-24 | 瑞泽恩制药公司 | 多功能等位基因 |
| ES2683071T3 (es) | 2012-04-25 | 2018-09-24 | Regeneron Pharmaceuticals, Inc. | Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento |
| US9510569B2 (en) * | 2013-03-13 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| HK1220990A1 (zh) * | 2013-08-07 | 2017-05-19 | 瑞泽恩制药公司 | 缺乏lincrna的非人类动物 |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| EP3460063B1 (en) | 2013-12-11 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| DK3152312T3 (da) | 2014-06-06 | 2020-04-06 | Regeneron Pharma | Fremgangsmåder og sammensætninger til modifikation af et mållocus |
| US9738897B2 (en) | 2014-06-23 | 2017-08-22 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated DNA assembly |
| DK3161128T3 (en) | 2014-06-26 | 2018-11-05 | Regeneron Pharma | METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF |
| BR112017007770A2 (pt) | 2014-10-15 | 2018-01-16 | Regeneron Pharma | cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc. |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| MX388784B (es) | 2014-12-19 | 2025-03-20 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa. |
| US10285387B2 (en) | 2015-03-16 | 2019-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| US11505792B2 (en) * | 2016-04-11 | 2022-11-22 | Applied Stemcell, Inc. | Site-specific integration of transgenes |
| SG10202102885UA (en) | 2016-05-20 | 2021-05-28 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| CN109803530A (zh) | 2016-07-29 | 2019-05-24 | 瑞泽恩制药公司 | 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠 |
| CN107779462B (zh) * | 2016-08-29 | 2021-06-04 | 中国科学院分子细胞科学卓越创新中心 | 双同源重组谱系示踪技术 |
| WO2018096356A1 (en) * | 2016-11-28 | 2018-05-31 | Horizon Discovery Limited | Methods for conditional gene knock-out |
| CA3049980A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| WO2019006034A1 (en) | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| ES2911249T3 (es) | 2017-11-10 | 2022-05-18 | Regeneron Pharma | Animales no humanos que comprenden una mutación de slc30a8 y métodos de uso |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| SG11202010891SA (en) | 2018-06-13 | 2020-11-27 | Regeneron Pharma | A rodent model of fibrodysplasia ossificans progressiva |
| WO2020131632A1 (en) | 2018-12-20 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated repeat expansion |
| EP3945800A1 (en) | 2019-04-03 | 2022-02-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| CA3140297A1 (en) * | 2019-06-19 | 2020-12-24 | Simon Auslaender | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| EP4171215A2 (en) | 2020-06-26 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| EP4259279A1 (en) | 2020-12-14 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
| WO2023076944A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy |
| EP4423271A2 (en) | 2021-10-28 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| EP4451863A1 (en) | 2021-12-20 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| AU2023269134A1 (en) | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2023220697A1 (en) * | 2022-05-12 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Inducible recombinase systems |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| JP7635182B2 (ja) * | 2022-08-04 | 2025-02-25 | 株式会社豊田中央研究所 | 相同組換え方法 |
| EP4565603A1 (en) | 2022-08-05 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
| KR20250144399A (ko) | 2023-02-01 | 2025-10-10 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 klhdc7b 유전자좌를 포함하는 동물 |
| IL324966A (en) | 2023-06-08 | 2026-01-01 | Regeneron Pharma | An animal model with rapid onset of Alzheimer's beta-amyloid plaque pathology |
| WO2025235388A1 (en) | 2024-05-06 | 2025-11-13 | Regeneron Pharmaceuticals, Inc. | Transgene genomic identification by nuclease-mediated long read sequencing |
| WO2026102284A1 (en) | 2024-11-08 | 2026-05-15 | Regeneron Pharmaceuticals, Inc. | Humanized stathmin2 allele to track human tdp-43-dependent splicing changes caused by tdp-43 pathology |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1092768A1 (en) * | 1999-10-16 | 2001-04-18 | ARTEMIS Pharmaceuticals GmbH | Conditional gene trapping construct for the disruption of genes |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
| US7074611B2 (en) * | 2001-04-27 | 2006-07-11 | Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) | Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| US7205148B2 (en) * | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
| US7582741B2 (en) * | 2004-07-26 | 2009-09-01 | University Of Massachusetts | Conditional disruption of dicer1 in cell lines and non-human mammals |
| EP1662005A1 (en) * | 2004-11-26 | 2006-05-31 | FrankGen Biotechnologie AG | Enhancer-containing gene trap vectors for random and targeted gene trapping |
| DE602005026221D1 (de) | 2004-11-26 | 2011-03-17 | Frankgen Biotechnologie Ag | Gen-fallen-kassette für eine gerichtete und ungerichtete konditionelle geninaktivierung |
| CN102666854B (zh) | 2009-10-29 | 2016-08-24 | 瑞泽恩制药公司 | 多功能等位基因 |
-
2010
- 2010-10-29 CN CN201080056458.9A patent/CN102666854B/zh active Active
- 2010-10-29 PL PL16196614T patent/PL3147362T3/pl unknown
- 2010-10-29 CA CA2779858A patent/CA2779858C/en active Active
- 2010-10-29 JP JP2012537099A patent/JP5908405B2/ja active Active
- 2010-10-29 CN CN201610565668.XA patent/CN106191126B/zh active Active
- 2010-10-29 AU AU2010319894A patent/AU2010319894B2/en active Active
- 2010-10-29 ES ES10774391.6T patent/ES2613662T3/es active Active
- 2010-10-29 PL PL10774391T patent/PL2494047T3/pl unknown
- 2010-10-29 EP EP10774391.6A patent/EP2494047B1/en active Active
- 2010-10-29 DK DK10774391.6T patent/DK2494047T3/en active
- 2010-10-29 ES ES16196614T patent/ES2716981T3/es active Active
- 2010-10-29 DK DK16196614.8T patent/DK3147362T3/en active
- 2010-10-29 WO PCT/US2010/054654 patent/WO2011059799A1/en not_active Ceased
- 2010-10-29 EP EP16196614.8A patent/EP3147362B1/en active Active
- 2010-10-29 US US12/915,447 patent/US20110104799A1/en not_active Abandoned
- 2010-10-29 PT PT16196614T patent/PT3147362T/pt unknown
- 2010-10-29 TR TR2019/03376T patent/TR201903376T4/tr unknown
- 2010-10-29 PT PT107743916T patent/PT2494047T/pt unknown
-
2013
- 2013-07-12 US US13/940,609 patent/US10392633B2/en active Active
-
2016
- 2016-02-01 JP JP2016017198A patent/JP6085696B2/ja active Active
- 2016-07-28 JP JP2016148272A patent/JP6333316B2/ja active Active
-
2017
- 2017-01-26 CY CY20171100118T patent/CY1118659T1/el unknown
-
2019
- 2019-03-26 CY CY20191100345T patent/CY1121457T1/el unknown
- 2019-07-01 US US16/459,236 patent/US11319557B2/en active Active
-
2022
- 2022-04-01 US US17/712,003 patent/US12473574B2/en active Active
-
2025
- 2025-10-17 US US19/362,036 patent/US20260234672A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185166A5 (cg-RX-API-DMAC10.html) | ||
| Wang et al. | Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos | |
| Lao et al. | MASTR: a technique for mosaic mutant analysis with spatial and temporal control of recombination using conditional floxed alleles in mice | |
| Elmonem et al. | Genetic renal diseases: the emerging role of zebrafish models | |
| Oji et al. | CRISPR/Cas9 mediated genome editing in ES cells and its application for chimeric analysis in mice | |
| Wang et al. | Intersectional Cre driver lines generated using split-intein mediated split-Cre reconstitution | |
| Reeves et al. | Dorsal-ventral gene expression in the Drosophila embryo reflects the dynamics and precision of the dorsal nuclear gradient | |
| US10863730B2 (en) | Gene knockout method | |
| Moro et al. | Generation and application of signaling pathway reporter lines in zebrafish | |
| Guo et al. | Targeted genome editing in primate embryos | |
| Cenik et al. | Severe myopathy in mice lacking the MEF2/SRF-dependent gene leiomodin-3 | |
| Wei et al. | Efficient introgression of allelic variants by embryo-mediated editing of the bovine genome | |
| CY1120808T1 (el) | Μεθοδοι και συνθεσεις για στοχευμενες γενετικες τροποποιησεις και μεθοδοι χρησης | |
| Jiang et al. | MOF influences meiotic expansion of H2AX phosphorylation and spermatogenesis in mice | |
| HRP20231707T1 (hr) | Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47 | |
| Zeng et al. | EHMT2 and SETDB1 protect the maternal pronucleus from 5mC oxidation | |
| Reichert et al. | Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression | |
| Fei et al. | 3′ UTR-dependent, miR-92-mediated restriction of Tis21 expression maintains asymmetric neural stem cell division to ensure proper neocortex size | |
| Jullien et al. | DNA methylation reprogramming during plant sexual reproduction? | |
| Grajevskaja et al. | Analysis of a conditional gene trap reveals that tbx5a is required for heart regeneration in zebrafish | |
| Fujii et al. | Repeatable construction method for engineered zinc finger nuclease based on overlap extension PCR and TA-cloning | |
| Shawlot et al. | Rfx2 is required for spermatogenesis in the mouse | |
| Coward et al. | In vivo gene transfer into testis and sperm: developments and future application | |
| Borodovsky et al. | Neural protein Olig2 acts upstream of the transcriptional regulator Sim1 to specify diencephalic dopaminergic neurons | |
| Kishimoto et al. | A novel tissue specific alternative splicing variant mitigates phenotypes in Ets2 frame-shift mutant models |